New fusion protein, useful for selective treatment of monocytic leukemia, comprises a lipopolysaccharide-binding protein and a cell-damaging domain, cytotoxic or immune-response promoting domain

摘要

A fusion protein (FP), comprising: (a) at least one lipopolysaccharide-binding protein (LBP), or a region of it; and (b) at least one cell-damaging domain, or a cytotoxic or immune-response promoting domain, is new. A fusion protein (FP), comprising: (a) at least one lipopolysaccharide-binding protein (LBP), or a region of it; and (b) at least one cell-damaging domain (CDD), or a cytotoxic or immune-response promoting domain, is new. The CDD is a microtubule-binding domain, HLA-B7, CD81 or CD86, endotoxin, GTP(guanosine triphosphate)-ase or -hydrolase, protease (e.g. subtilisin), nuclease (e.g. RNase or DNase, e.g. S1 endonuclease), other enzymes, cytochrome C, death domain, death effector domain, the Fc region of an antibody or at least one other domain. Independent claims are also included for: (1) a nucleic acid sequence encoding for the FP; (2) a vector containing the nucleic acid encoding for the FP; (3) a cloning/expression system for the FP; and (4) a complex (C) of lipopolysaccharide with FP.